| November 9, 2026 | FDA requires GLP-1 labelling changes concerning a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. | All clinical programmes and dispensing partners | Medical director: review counselling, escalation and partner materials. (fda.gov) |
| November 10, 2026 | FTC’s Hims & Hers case records an amended complaint; five additional states joined the privacy and billing litigation. These remain allegations, not adjudicated findings. | Telehealth platforms, subscription clinics and integrated access vendors | Compliance: review data sharing, charging triggers and cancellation workflows. (ftc.gov) |
| October 30, 2026 | HHS publishes notice of a draft/interim enforcement-discretion policy for specified peptide substances—not a general GLP-1 compounding permission. | Clinics receiving peptide-expansion proposals | Counsel: reject extrapolation beyond the substances and conditions actually listed. (govinfo.gov) |
| September 18, 2026 | FDA’s Empower Pharmacy warning letter challenges apparently copied GLP-1 preparations and supporting patient-difference documentation. | Clinics relying on patient-specific compounding | Audit prescribing templates and evidence supporting formulation changes. (fda.gov) |
| August 27, 2026; semaglutide opinion revised September 1 | Fifth Circuit opinions affirm judgments supporting FDA’s tirzepatide and semaglutide shortage decisions. | Buyers relying on litigation to preserve shortage-era supply | Require the actual order behind any claimed litigation protection. (ca5.uscourts.gov) |
| August 12, 2026 | FDA letter addresses compounded GLP-1 multidose-vial labelling, dosing confusion and use beyond the customary post-puncture period. | Clinical, procurement and finance teams | Reconcile vial size, discard instructions and usable supply before accepting quotes. (azbn.gov) |
| August 6, 2026 | FDA grants an additional year of specified DSCSA exemptions for qualifying small dispensers, through November 27, 2027. | Pharmacy owners and clinic-stock supply chains | Document eligibility and the obligations that remain applicable. (fda.gov) |
| July 1, 2026 | Medicare GLP-1 Bridge launches; eligible beneficiaries can access selected products for a $50 monthly copay, through December 31, 2027. | Clinics serving Medicare beneficiaries | Add eligibility screening and pharmacy claims-routing tests. (cms.gov) |
| April 30 announcement; May 1, 2026 publication | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. | Buyers considering outsourcing facilities | Treat as a proposal, not a newly effective blanket ban or temporary permission. (fda.gov) |